The development and implementation of R21/Matrix-M was the result of a tremendous collaborative effort between the Jenner Institute, University of Oxford, Serum Institute of India Pvt. Ltd. and all the sites involved in the clinical trials; IRSS Burkina Faso, Malaria Research and Training Center/USTTB /Laboratory of Malaria Immunology and Vaccinology, KEMRI - Wellcome Trust, Institut des Sciences et Techniques (INSTech), Bobo-Dioulasso, Burkina Faso and Ifakara Health Research Institute.
As of April 2025, R21/Matrix-M has been distributed in 12 malaria-endemic countries, where it will be instrumental in the fight against Malaria.